NASDAQ:FCSC - Fibrocell Stock Price, Price Target & More

$0.59 0.00 (0.00 %)
(As of 04/25/2018 10:36 AM ET)
Previous Close$0.59
Today's Range$0.56 - $0.59
52-Week Range$0.51 - $4.64
Volume31,737 shs
Average Volume552,801 shs
Market Capitalization$16.73 million
P/E Ratio-0.36
Dividend YieldN/A
Beta0.48

About Fibrocell (NASDAQ:FCSC)

Fibrocell logoFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

Receive FCSC News and Ratings via Email

Sign-up to receive the latest news and ratings for FCSC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FCSC
CUSIPN/A
Phone484-713-6000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.05%
Quick Ratio4.05%

Price-To-Earnings

Trailing P/E Ratio-0.36
Forward P/E Ratio-0.83
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales47.81
Cash FlowN/A
Price / CashN/A
Book Value$0.35 per share
Price / Book1.69

Profitability

EPS (Most Recent Fiscal Year)($1.65)
Net Income$-16,240,000.00
Net MarginsN/A
Return on Equity-649.57%
Return on Assets-111.79%

Miscellaneous

Employees20
Outstanding Shares28,360,000

How to Become a New Pot Stock Millionaire

Fibrocell (NASDAQ:FCSC) Frequently Asked Questions

What is Fibrocell's stock symbol?

Fibrocell trades on the NASDAQ under the ticker symbol "FCSC."

How were Fibrocell's earnings last quarter?

Fibrocell (NASDAQ:FCSC) posted its quarterly earnings results on Monday, March, 19th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.42. View Fibrocell's Earnings History.

When is Fibrocell's next earnings date?

Fibrocell is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Fibrocell.

What price target have analysts set for FCSC?

3 analysts have issued 12 month target prices for Fibrocell's shares. Their forecasts range from $6.00 to $7.00. On average, they expect Fibrocell's share price to reach $6.50 in the next twelve months. View Analyst Ratings for Fibrocell.

Who are some of Fibrocell's key competitors?

Who are Fibrocell's key executives?

Fibrocell's management team includes the folowing people:
  • Mr. John Michael Maslowski, Pres, CEO, PFO, Principal Accounting Officer & Director (Age 43)
  • Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor Relations
  • Ms. Elizabeth A. Browning, Exec. VP of Marketing
  • Ms. Michele Mchugh-Mazzatta, VP of Sales
  • Dr. Pierre Compte, Managing Director of Switzerland

Has Fibrocell been receiving favorable news coverage?

News coverage about FCSC stock has been trending somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fibrocell earned a news sentiment score of 0.10 on Accern's scale. They also gave press coverage about the company an impact score of 44.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Fibrocell?

Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fibrocell's stock price today?

One share of FCSC stock can currently be purchased for approximately $0.59.

How big of a company is Fibrocell?

Fibrocell has a market capitalization of $16.73 million and generates $350,000.00 in revenue each year. The company earns $-16,240,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Fibrocell employs 20 workers across the globe.

How can I contact Fibrocell?

Fibrocell's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected]


MarketBeat Community Rating for Fibrocell (FCSC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Fibrocell and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fibrocell (NASDAQ:FCSC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Fibrocell in the last 12 months. Their average twelve-month price target is $6.50, suggesting that the stock has a possible upside of 1,001.69%. The high price target for FCSC is $7.00 and the low price target for FCSC is $6.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.50$6.50$5.00$5.5333
Price Target Upside: 1,001.69% upside983.33% upside566.67% upside83.22% upside

Fibrocell (NASDAQ:FCSC) Consensus Price Target History

Price Target History for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ:FCSC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2018Griffin SecuritiesReiterated RatingBuyLowView Rating Details
3/19/2018HC WainwrightSet Price TargetBuy$6.00MediumView Rating Details
9/11/2017Canaccord GenuityReiterated RatingBuy$3.00 -> $7.00LowView Rating Details
3/7/2017Rodman & RenshawInitiated CoverageBuy -> Buy$2.00N/AView Rating Details
6/8/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
6/8/2016WedbushReiterated RatingNeutral$1.50 -> $4.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Fibrocell (NASDAQ:FCSC) Earnings History and Estimates Chart

Earnings by Quarter for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ:FCSC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.23)($0.23)($0.23)

Fibrocell (NASDAQ FCSC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.17)N/AView Earnings Details
3/19/2018Q4 2017($0.23)($0.65)ViewListenView Earnings Details
11/13/2017Q3 2017($0.41)($0.34)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.31)($0.31)ViewListenView Earnings Details
5/10/2017Q1 2017($0.29)($0.58)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.81)($0.33)$0.02 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q316($0.15)($0.05)$0.07 million$0.22 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.39)($0.42)$0.04 million$0.09 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.48)$0.12$0.07 million$0.02 millionViewN/AView Earnings Details
3/10/2016Q415($0.17)($0.40)$0.07 million$0.08 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.07)$0.06 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q215($0.16)($0.17)$0.09 million$0.14 millionViewN/AView Earnings Details
5/8/2015Q1 2015($0.16)($0.17)$0.05 million$0.19 millionViewN/AView Earnings Details
3/13/2015Q4 2014($0.16)($0.16)$0.06 million$0.06 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.14)($0.17)$0.06 million$0.02 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.18)($0.08)$0.07 million$0.06 millionViewN/AView Earnings Details
5/19/2014Q114($0.15)($0.35)$0.05 million$0.05 millionViewN/AView Earnings Details
3/17/2014Q414($0.26)($0.14)$0.05 million$0.04 millionViewN/AView Earnings Details
11/14/2013Q3 2013($0.63)($1.44)$0.07 million$0.07 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.66)$0.03 millionViewN/AView Earnings Details
11/17/2011Q3 2011($4.50)($1.35)ViewN/AView Earnings Details
8/15/2011Q2 2011($23.85)ViewN/AView Earnings Details
5/18/2011Q1 2011($9.75)($14.33)ViewN/AView Earnings Details
11/18/2010Q3 2010($6.98)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Fibrocell (NASDAQ:FCSC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Fibrocell (NASDAQ FCSC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 44.44%
Insider Trading History for Fibrocell (NASDAQ:FCSC)
Institutional Ownership by Quarter for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ FCSC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2017Randal J KirkMajor ShareholderBuy2,727,273$0.77$2,100,000.21View SEC Filing  
12/2/2016David PernockChairmanBuy50,000$0.92$46,000.00105,600View SEC Filing  
11/13/2015David PernockCEOBuy3,000$5.00$15,000.0055,600View SEC Filing  
8/11/2015David PernockCEOBuy3,500$6.54$22,890.00View SEC Filing  
7/27/2015Randal J KirkMajor ShareholderBuy975,987$5.80$5,660,724.60View SEC Filing  
5/13/2015David PernockCEOBuy16,600$4.30$71,380.00View SEC Filing  
12/12/2014David PernockCEOBuy5,000$2.52$12,600.00View SEC Filing  
11/20/2014David PernockCEOBuy5,000$2.54$12,700.00View SEC Filing  
11/20/2014John Michael MaslowskiVPBuy1,000$2.54$2,540.00View SEC Filing  
6/5/2014Christine St.ClareDirectorBuy10,000$3.00$30,000.00View SEC Filing  
6/5/2014David PernockCEOBuy12,500$2.95$36,875.00View SEC Filing  
6/4/2014Kelvin MooreDirectorBuy4,557$2.99$13,625.43View SEC Filing  
6/4/2014Randal J KirkMajor ShareholderBuy400,000$2.90$1,160,000.00View SEC Filing  
1/24/2014Randal J KirkMajor ShareholderBuy1,024,590$4.88$4,999,999.20View SEC Filing  
11/21/2013David PernockCEOBuy10,000$3.69$36,900.00View SEC Filing  
11/20/2013Gregory L WeaverCFOBuy10,000$3.51$35,100.00View SEC Filing  
10/1/2013Randal J KirkMajor ShareholderBuy3,658,536$4.10$14,999,997.60View SEC Filing  
7/26/2013Randal J KirkMajor ShareholderBuy1,243,781$6.03$7,499,999.43View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fibrocell (NASDAQ FCSC) News Headlines

Source:
DateHeadline
Fibrocell (FCSC) Rating Increased to Buy at Zacks Investment ResearchFibrocell (FCSC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:28 AM
Form 8-K Fibrocell Science, Inc. For: Apr 18Form 8-K Fibrocell Science, Inc. For: Apr 18
www.streetinsider.com - April 18 at 5:45 PM
Health Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRXHealth Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRX
www.nasdaq.com - April 18 at 5:45 PM
BRIEF-Fibrocell Announces Review Of Strategic AlternativesBRIEF-Fibrocell Announces Review Of Strategic Alternatives
www.reuters.com - April 18 at 5:45 PM
Fibrocell Announces Review of Strategic AlternativesFibrocell Announces Review of Strategic Alternatives
globenewswire.com - April 18 at 8:16 AM
Fibrocell Science shares halted pending newsFibrocell Science shares halted pending news
seekingalpha.com - April 18 at 8:10 AM
Fibrocell (FCSC) Expected to Announce Earnings of -$0.17 Per ShareFibrocell (FCSC) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM
Fibrocell Science (FCSC) Lowered to "Sell" at ValuEngineFibrocell Science (FCSC) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 8:37 PM
Fibrocell Science (FCSC) Given a $6.00 Price Target at HC WainwrightFibrocell Science (FCSC) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 11 at 7:53 PM
Fibrocell Science (FCSC) Rating Lowered to Sell at Zacks Investment ResearchFibrocell Science (FCSC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 10 at 5:02 PM
Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USAFibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
finance.yahoo.com - April 10 at 8:27 AM
Fibrocell Science (FCSC) Cut to Strong Sell at ValuEngineFibrocell Science (FCSC) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM
Fibrocell Science (FCSC) Receives "Buy" Rating from Griffin SecuritiesFibrocell Science (FCSC) Receives "Buy" Rating from Griffin Securities
www.americanbankingnews.com - April 6 at 9:10 AM
Zacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.22 Per ShareZacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - March 30 at 1:20 PM
Reviewing OptiNose (OPTN) & Fibrocell Science (FCSC)Reviewing OptiNose (OPTN) & Fibrocell Science (FCSC)
www.americanbankingnews.com - March 30 at 9:38 AM
Fibrocell Science (FCSC) PT Set at $6.00 by HC WainwrightFibrocell Science (FCSC) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 2:06 PM
Zacks Investment Research Lowers Fibrocell Science (FCSC) to HoldZacks Investment Research Lowers Fibrocell Science (FCSC) to Hold
www.americanbankingnews.com - March 24 at 12:28 AM
Fibrocell Sciences (FCSC) CEO John Maslowski on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaFibrocell Science's (FCSC) CEO John Maslowski on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 20 at 8:28 AM
Fibrocell Science (FCSC) Releases  Earnings Results, Beats Estimates By $0.38 EPSFibrocell Science (FCSC) Releases Earnings Results, Beats Estimates By $0.38 EPS
www.americanbankingnews.com - March 19 at 1:48 PM
HC Wainwright Analysts Give Fibrocell Science (FCSC) a $6.00 Price TargetHC Wainwright Analysts Give Fibrocell Science (FCSC) a $6.00 Price Target
www.americanbankingnews.com - March 19 at 1:03 PM
Earnings Scheduled For March 19, 2018 - BenzingaEarnings Scheduled For March 19, 2018 - Benzinga
www.benzinga.com - March 19 at 8:22 AM
Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future?Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future?
finance.yahoo.com - March 19 at 8:22 AM
Fibrocell Reports 2017 Financial Results and Recent HighlightsFibrocell Reports 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 19 at 8:22 AM
Pre-Market Earnings Report for March 19, 2018 : CSIQ, MDWD, LEJU, FCSC - NasdaqPre-Market Earnings Report for March 19, 2018 : CSIQ, MDWD, LEJU, FCSC - Nasdaq
www.nasdaq.com - March 17 at 8:26 AM
Fibrocell Science Inc (FCSC) Sees Large Decrease in Short InterestFibrocell Science Inc (FCSC) Sees Large Decrease in Short Interest
www.americanbankingnews.com - March 14 at 1:38 AM
Fibrocell Science (FCSC) Rating Increased to Buy at Zacks Investment ResearchFibrocell Science (FCSC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:52 PM
Zacks: Brokerages Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 13 at 12:03 PM
Fibrocell Science (FCSC) Set to Announce Quarterly Earnings on MondayFibrocell Science (FCSC) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 13 at 10:56 AM
Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - GlobeNewswire (press release)Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM
Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - NasdaqFibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - Nasdaq
www.nasdaq.com - March 12 at 9:02 AM
Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent HighlightsFibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 12 at 9:02 AM
Fibrocell Science (FCSC) Stock Rating Lowered by Zacks Investment ResearchFibrocell Science (FCSC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 7 at 11:22 PM
Fibrocell Science (FCSC) Upgraded to Buy at Zacks Investment ResearchFibrocell Science (FCSC) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 6 at 10:52 PM
Fibrocell Sciences (FCSC) Buy Rating Reiterated at HC WainwrightFibrocell Science's (FCSC) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 6 at 3:28 PM
Fibrocell Science (FCSC) Announces FDA Allowance of IND for FCX-013 for Treatment of Moderate to Severe ... - StreetInsider.comFibrocell Science (FCSC) Announces FDA Allowance of IND for FCX-013 for Treatment of Moderate to Severe ... - StreetInsider.com
www.streetinsider.com - March 6 at 8:15 AM
Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaFibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
finance.yahoo.com - March 6 at 8:15 AM
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat - NasdaqIntrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat - Nasdaq
www.nasdaq.com - March 3 at 8:16 AM
Fibrocell Science (FCSC) Set to Announce Quarterly Earnings on WednesdayFibrocell Science (FCSC) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:40 AM
Whats in Store for Intrexon (XON) This Earnings Season?What's in Store for Intrexon (XON) This Earnings Season?
www.msn.com - February 27 at 8:19 AM
Comparing Organovo (ONVO) & Fibrocell Science (FCSC)Comparing Organovo (ONVO) & Fibrocell Science (FCSC)
www.americanbankingnews.com - February 17 at 12:26 PM
Fibrocell Science (FCSC) Rating Lowered to Hold at Zacks Investment ResearchFibrocell Science (FCSC) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 14 at 11:42 PM
Zacks Investment Research Upgrades Fibrocell Science (FCSC) to BuyZacks Investment Research Upgrades Fibrocell Science (FCSC) to Buy
www.americanbankingnews.com - February 14 at 12:28 AM
Zacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 7 at 11:16 AM
Fibrocell Science (FCSC) Lowered to "Hold" at Zacks Investment ResearchFibrocell Science (FCSC) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 11:06 PM
Fibrocell to Present at 20th Annual BIO CEO & Investor ConferenceFibrocell to Present at 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:28 AM
Fibrocell Science (FCSC) Lifted to "Buy" at Zacks Investment ResearchFibrocell Science (FCSC) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - February 5 at 11:24 PM
BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin DisorderBRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder
www.reuters.com - February 5 at 9:34 AM
Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaFibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
finance.yahoo.com - February 5 at 9:34 AM
Wired News – Fibrocell Science Gets FDA Allowance to Start Pediatric Enrollment in Phase-1/2 Clinical Trial of FCX-007 for the Treatment of RDEBWired News – Fibrocell Science Gets FDA Allowance to Start Pediatric Enrollment in Phase-1/2 Clinical Trial of FCX-007 for the Treatment of RDEB
finance.yahoo.com - February 1 at 9:40 AM
Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
finance.yahoo.com - January 30 at 9:22 AM

SEC Filings

Fibrocell (NASDAQ:FCSC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fibrocell (NASDAQ:FCSC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fibrocell (NASDAQ FCSC) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.